Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals — FY2017 Earnings Presentation

25 slides from Avadel Pharmaceuticals's earnings presentation, Mar 8, 2018

  1. Slide 1: Fourth Quarter & Full Year 2017 Results

    Fourth Quarter & Full Year 2017 Results March 8, 2018

  2. Slide 2: Safe Harbor

    2 Safe Harbor This presentation may include forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 . The words “will,” “may,” “believe,” “expect,” “anticipate,” “estimate,” “project” and similar expression

  3. Slide 3: Call Outline

    3 Call Outline I. Fourth quarter & full year 2017 overview II. REST - ON Phase III trial update III. FT 218: Pharmacokinetic overview IV. Market update: i. Sodium oxybate use and persistence rates ii. Concomitant use of sodium oxybate and sodium valproate iii. Noctiva ™ V. Q&A

  4. Slide 4: Recent Highlights

    4 Recent Highlights Financial Overview • 4Q 2017 revenues of $34.2 million & adjusted LPS of $(0.28) • 2017 total revenues of $172.7 million & adjusted EPS of $0.31 • Repurchased $22.3 million of shares • Operating cash flow positive • $137.7 million in net proceeds from convertible offering (2/14/1

  5. Slide 5: Fourth Quarter & Full Year 2017 Financial Results

    5 Fourth Quarter & Full Year 2017 Financial Results

  6. Slide 6: Non-GAAP Financial Results

    6 Non - GAAP Financial Results *Reconciliations from GAAP to Non - GAAP can be found in the appendix (in $000s, except for per share amounts 12/31/17 09/30/17 12/31/16 12/31/17 12/31/16 Total revenue 34,590$ 39,675$ 43,085$ 174,183$ 150,246$ Cost of products and services sold 4,048 3,790 3,610 16,25

  7. Slide 7: GAAP Financial Results

    7 GAAP Financial Results (in $000s, except for per share amounts 12/31/17 09/30/17 12/31/16 12/31/17 12/31/16 Total revenue 34,248$ 39,675$ 43,085$ 172,741$ 150,246$ Cost of products and services sold 4,048 3,790 2,591 16,301 13,248 Research and development expenses 12,125 8,095 13,476 34,218 34,611

  8. Slide 8: Cash Flow Summary

    8 Cash Flow Summary in $000's 2017 2016 TOTAL Cash and Marketable Securities Beginning Balance 154,195$ 144,802$ Operating cash flows (excl tax and earnout payments) - base business 86,870 68,801 Noctiva operating spending (15,000) - Earnout/Royalty Payments (37,311) (30,837) Tax Payments (19,143) (

  9. Slide 9: 2018 Non-GAAP Guidance

    9 2018 Non - GAAP Guidance 2018 Guidance Current Previous Total Revenues $1 05 M - $1 25 M $1 10 M - $1 30 M Noctiva Revenues $10M - $20M $10M - $20M R&D Expense $ 40 M - $ 50 M $ 40 M - $ 50 M Income Ta x Benefit 0 % - 10 % - Guidance update driven by divestiture of pediatric assets in February 201

  10. Slide 10: REST-ON Phase III Clinical Update & PK Overview

    10 REST - ON Phase III Clinical Update & PK Overview

  11. Slide 11: REST-ON Status Update

    11 REST - ON Status Update NDA filing by year end 2018 no longer expected Recent enrollment rate increases are not meeting expectations Activating new clinical sites and increasing patient engagement initiatives to improve screening and enrollment Update on trial to be provided in 2H 2018

  12. Slide 12: Pharmacokinetics: FT vs. Twice-Nightly

    12 Pharmacokinetics: FT 218 vs. Twice - Nightly • 3 FT 218 prototypes at 4.5g vs approved 2 x 2.25g doses • Cmax of FT 218 avoids high peak levels of sodium oxybate associated with second dose • With preferred formulations blood concentration higher first 4 hours with gradual decline • FT 218 simila

  13. Slide 13: Pharmacokinetics: FT at 4.5g, 6g & 7.5g Doses

    13 Pharmacokinetics: FT 218 at 4.5g, 6g & 7.5g Doses • PK for doses at 4.5g, 6g, 7.5g • Consistency and linearity of response as dose increased • Robust and reproducible across dose strengths • Remove inconsistency in timing or missing of second dose

  14. Slide 14: Market Update: Sodium Oxybate & Noctiva

    14 Market Update: Sodium Oxybate & Noctiva ™

  15. Slide 15: Sodium Oxybate: Market Research Highlights

    15 Sodium Oxybate: Market Research Highlights 3 - year longitudinal claims analysis & market assessment identifying 262K diagnosed narcolepsy patients Of 262K patients, 194K were treated pharmacologically 19K unique patients (~10%) received 2x - nightly sodium oxybate <1% of 19K patients received so

  16. Slide 16: Sodium Oxybate: Market Research Highlights

    16 Sodium Oxybate: Market Research Highlights Significant interest from patients in 1x - night given tolerability & dosing Cost assessment: Current & only approved product’s price increased ~1,600% 1 since 2006 Est. 70% of 2x - nightly product revenue increase in last 5 years was price driven, with

  17. Slide 17: Noctiva: Launch Update

    17 Noctiva ™: Launch Update Accelerated launch >4 weeks ahead of schedule – shipments to wholesalers have begun Patient assistance programs fully operational, including retail & specialty / mail order Fully staffed sales force initiating early access programs & PI launch 4/1/18; Branded launch 5/1 E

  18. Slide 18: Question & Answer

    18 Question & Answer

  19. Slide 19: Appendix

    19 Appendix

  20. Slide 20: Revenues by Product (GAAP)

    20 Revenues by Product (GAAP) in $000's Q1 2017 Q2 2017 Q3 2017 Q4 2017 Full Year 2017 Full Year 2016 Bloxiverz 13,902$ 13,719$ 9,920$ 7,763$ 45,304$ 82,896$ Vazculep 10,179 10,154 9,573 8,140 38,046 39,796 Akovaz 25,638 20,912 18,561 15,435 80,546 16,831 Other 2,038 2,320 1,093 2,990 8,441 7,699 To

  21. Slide 21: GAAP to Non-GAAP Reconciliations: 4Q 2017

    21 GAAP to Non - GAAP Reconciliations: 4Q 2017 Include GAAP Intangible asset amortization Foreign exchange (loss) gain Restructuring impacts License Revenue Adjustment U.S. Federal Tax Law Change Contingent related party payable fair value remeasurements Contingent related party payable paid/accrued

  22. Slide 22: GAAP to Non-GAAP Reconciliations: 3Q 2017

    22 GAAP to Non - GAAP Reconciliations: 3Q 2017 Include GAAP Intangible asset amortization Foreign exchange (loss) gain Cross-border merger impacts Purchase accounting adjustments - FSC Contingent related party payable fair value remeasurements Contingent related party payable paid/accrued Total Adju

  23. Slide 23: GAAP to Non-GAAP Reconciliations: 4Q 2016

    23 GAAP to Non - GAAP Reconciliations: 4Q 2016 Include GAAP Intangible asset amortization Foreign exchange (loss) gain Cross-border merger impacts Purchase accounting adjustments - FSC Contingent related party payable fair value remeasurements Contingent related party payable paid/accrued Total Adju

  24. Slide 24: GAAP to Non-GAAP Reconciliations: FY 2017

    24 GAAP to Non - GAAP Reconciliations: FY 2017 Include GAAP Intangible asset amortization Foreign exchange (loss) gain Restructuring impacts Purchase accounting adjustments - FSC License Revenue Adjustment U.S. Federal Tax Law Change Contingent related party payable fair value remeasurements Conting

  25. Slide 25: GAAP to Non-GAAP Reconciliations: FY 2016

    25 GAAP to Non - GAAP Reconciliations: FY 2016 Include GAAP IntAIgible asset amortization Foreign exchange (loss) gain Cross-border merger impacts Purchase accounting adjustments - FSC Contingent related party payable fair value remeasurements Contingent related party payable paid/accrued Total Adju

Avadel Pharmaceuticals — FY2017 Earnings Presentation on 6ix